Chronic kidney disease (CKD) is associated with significant alterations in lipid metabolism, leading to an increased risk of cardiovascular morbidity and mortality. Dyslipidemia in CKD patients is characterized by elevated triglycerides, reduced high-density lipoprotein (HDL), and variable low-density lipoprotein (LDL) levels. Appropriate use of antihyperlipidemic drugs plays a critical role in reducing cardiovascular risk in this population. This study aims to evaluate the prescribing patterns of antihyperlipidemic drugs in CKD patients, focusing on drug selection, dosage adjustments, and adherence to clinical guidelines. Commonly prescribed agents include statins, fibrates, ezetimibe, and combination therapies. The study also assesses the pharmacological mechanisms, safety profiles, and potential adverse effects of these drugs in CKD patients. Findings suggest that statins remain the cornerstone of therapy, though dose adjustments and careful monitoring are essential due to altered pharmacokinetics in CKD. Rational prescribing practices can significantly improve patient outcomes while minimizing drug related complications.2
Anila N.*, Soumya R. V.2, Dr. Nithin Manohor3, B. Aswinipriya1, Atmaj1, Roshin Robert1, Dr. Prasobh4 (Wed,) studied this question.